The efficacy and safety of sodium nitroprusside in the treatment of schizophrenia: Protocol for an updated systematic review and meta-analysis
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0283185 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, 2023. Verfasst von Xinxing Fei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Chengdu Eighth People's Hospital (Geriatric Hospital of Chengdu Medical College), Chengdu, Sichuan, People's Republic of Ch…. Hauptthemen laut MEDLINE: Medicine, Chinese Traditional, Drugs, Chinese Herbal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: School-level scientific research project of Southwest Medical University.
Abstract (Originalsprache)
Background Schizophrenia is a chronic persistent disease with high recurrence rate and high disability rate in the field of psychiatry. Sodium nitroprusside is a nitric oxide (NO) donor and considered a promising new compound for the treatment of schizophrenia. New high-quality clinical trials of sodium nitroprusside in the treatment of schizophrenia have been published in recent years. It is necessary to re-conduct the meta-analysis after the inclusion of these new clinical trials. Our study will conduct a systematic review and meta-analysis of the relevant literature in this field, so as to lay an evidence-based medicine foundation for the efficacy of sodium nitroprusside in the treatment of schizophrenia. Methods and analysis Randomized controlled trials (RCTs) of sodium nitroprusside in the treatment of schizophrenia were searched through English databases (PubMed, Web of Science, Embase, and Cochrane Library) and Chinese databases (China Biology Medicine disc, VIP, WanFang Data, and CNKI). The extracted data will be inputted into Review Manager 5.3 for Meta-analysis. The included literature will be assessed for bias risk according to the bias risk assessment tools in the Cochrane Handbook for Systematic Reviews of Interventions. Funnel plots will be used to assess possible publication bias. Heterogeneity is tested by I2 and χ2 tests, and the existence of heterogeneity is defined as I2 ≥50% and P ≤0.1. If heterogeneity exists, the random-effect model will be used, and sensitivity analysis or subgroup analysis will be performed to further determine the source of heterogeneity. Prospero registration number CRD42022341681 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Chengdu Eighth People's Hospital (Geriatric Hospital of Chengdu Medical College), Chengdu, Sichuan, People's Republic of China.
- Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
- Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, People's Republic of China.
- Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
- Department of Rehabilitation Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, People's Republic of China.
ORCID-Profile: Yue Hu
Förderung
- School-level scientific research project of Southwest Medical University
Zitieren
APA
Fei, X., Wang, S., Li, J., Wang, J., Gao, Y., & Hu, Y. (2023). The efficacy and safety of sodium nitroprusside in the treatment of schizophrenia: Protocol for an updated systematic review and meta-analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0283185
Vancouver
Fei X, Wang S, Li J, Wang J, Gao Y, Hu Y. The efficacy and safety of sodium nitroprusside in the treatment of schizophrenia: Protocol for an updated systematic review and meta-analysis. PLOS ONE. 2023. doi:10.1371/journal.pone.0283185
BibTeX
@article{Fei2023,
author = {Fei, Xinxing and Wang, Shiqi and Li, Jiyang and Wang, Jianxiong and Gao, Yaqian and Hu, Yue},
title = {The efficacy and safety of sodium nitroprusside in the treatment of schizophrenia: Protocol for an updated systematic review and meta-analysis},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0283185}
}
EUVIMED